BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS

The invention provides a compound of formula (0):or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein:n is 1 or 2;X is CH or N;Y is selected from CH and C-F;Z is selected from C-Rz and N;R1 is selected from:-(Alk1)t-Cyc1; wherein t is 0 or 1;Optionally substituted C1-6 acyclic hydrocarbon groupsR2 is selected from hydrogen; halogen; and C1-8 hydrocarbon groups optionally substituted with one or more fluorine atoms;R3 is hydrogen or a group L1-R7;R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; andR4a is selected from hydrogen and a C1-3 alkyl group;wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein;provided that the compound is other than 6-benzyl-3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof.The compounds are inhibitors of ERK1/2 kinases and will be useful in the treatment of ERK1/2-mediated conditions. The compounds are therefore useful in therapy, in particular in the treatment of cancer.